InMode (INMD) Cash from Financing Activities (2018 - 2026)
InMode (INMD) posted quarterly Cash from Financing Activities of -$32.4 million for Q1 2026, up 67.4% year-on-year from -$19.4 million in Q1 2025, and down 23768.61% on a QoQ basis from $137000.0 in Q4 2025.
InMode (INMD) Cash from Financing Activities (2018 - 2026) Analysis & Trends
InMode (INMD) has reported Cash from Financing Activities for 9 consecutive years, with -$32.4 million the latest figure, recorded in Q1 2026.
- Quarterly Cash from Financing Activities rose 67.4% year-over-year to -$32.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$59.0 million (up 84.57% YoY) and the FY2025 annual result came in at -$126.1 million, up 55.42% from the prior year.
- Cash from Financing Activities slipped to -$32.4 million in Q1 2026 per INMD's latest filing, from $137000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for INMD reached as high as $2.7 million in Q3 2023 and fell as low as -$118.4 million in Q4 2024.
- A 5-year average of -$28.0 million and a median of $204000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 396.18% — and 2024, when it plunged 43165.09%.
- Year by year, Cash from Financing Activities stood at $637000.0 in 2022, then tumbled by 56.83% to $275000.0 in 2023, then tumbled by 43165.09% to -$118.4 million in 2024, then soared by 100.12% to $137000.0 in 2025, then tumbled by 23768.61% to -$32.4 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$32.4 million, $137000.0, and $249000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | InMode | 956,721.10 | -479.17 Mn | 61.55 Mn | -32.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.43 Mn |
| Mar 31, 2026 | -32.43 Mn |
| Dec 31, 2025 | 137,000.00 |
| Dec 31, 2025 | 137,000.00 |
| Sep 30, 2025 | 249,000.00 |
| Sep 30, 2025 | 249,000.00 |
| Jun 30, 2025 | -26.98 Mn |
| Jun 30, 2025 | -26.98 Mn |
| Mar 31, 2025 | -99.47 Mn |
| Mar 31, 2025 | -99.47 Mn |
| Dec 31, 2024 | -118.43 Mn |
| Dec 31, 2024 | -118.43 Mn |
| Sep 30, 2024 | -75.99 Mn |
| Sep 30, 2024 | -75.99 Mn |
| Jun 30, 2024 | -88.59 Mn |
| Jun 30, 2024 | -88.59 Mn |
| Mar 31, 2024 | 234,000.00 |
| Mar 31, 2024 | 234,000.00 |
| Dec 31, 2023 | 275,000.00 |
| Dec 31, 2023 | 275,000.00 |